Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Gynecology

Free Subscription Articles published in Oncogene Retrieve available abstracts of 28 articles: HTML format

Single Articles

March 2023
1. MOSKOVICH D, Finkelshtein Y, Alfandari A, Rosemarin A, et al
   Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
   Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02629.
   PubMed    
   
   
   
2. CHEN K, Yuan X, Wang S, Zheng F, et al
   MAP4K4 promotes ovarian cancer metastasis through diminishing ADAM10-dependent N-cadherin cleavage.
   Oncogene. 2023 Mar 15. doi: 10.1038/s41388-023-02650.
   PubMed     Abstract available
   
   
   January 2023
3. ZHANG C, Jiang H, Yuan L, Liao Y, et al
   CircVPRBP inhibits nodal metastasis of cervical cancer by impeding RACK1 O-GlcNAcylation and stability.
   Oncogene. 2023 Jan 19. doi: 10.1038/s41388-023-02595.
   PubMed     Abstract available
   
   
   December 2022
4. LI G, Yi X, Du S, Gong L, et al
   Tumour-derived exosomal piR-25783 promotes omental metastasis of ovarian carcinoma by inducing the fibroblast to myofibroblast transition.
   Oncogene. 2022 Dec 8. doi: 10.1038/s41388-022-02560.
   PubMed     Abstract available
   
   
   November 2022
5. WANG M, Yan Q, Song Y, Zhang Z, et al
   Loss-of-function mutations of SOX17 lead to YAP/TEAD activation-dependent malignant transformation in endometrial cancer.
   Oncogene. 2022 Nov 29. doi: 10.1038/s41388-022-02550.
   PubMed     Abstract available
   
   
   
6. HE Y, OuYang Z, Liu W, Chen Y, et al
   TARDBP promotes ovarian cancer progression by altering vascular endothelial growth factor splicing.
   Oncogene. 2022 Nov 11. pii: 10.1038/s41388-022-02539.
   PubMed     Abstract available
   
   
   October 2022
7. HUANG TT, Burkett SS, Tandon M, Yamamoto TM, et al
   Distinct roles of treatment schemes and BRCA2 on the restoration of homologous recombination DNA repair and PARP inhibitor resistance in ovarian cancer.
   Oncogene. 2022 Oct 12. pii: 10.1038/s41388-022-02491.
   PubMed     Abstract available
   
   
   August 2022
8. DU QY, Huo FC, Du WQ, Sun XL, et al
   METTL3 potentiates progression of cervical cancer by suppressing ER stress via regulating m6A modification of TXNDC5 mRNA.
   Oncogene. 2022 Aug 20. pii: 10.1038/s41388-022-02435.
   PubMed     Abstract available
   
   
   July 2022
9. SHEN Z, Gu L, Liu Y, Wang L, et al
   PLAA suppresses ovarian cancer metastasis via METTL3-mediated m(6)A modification of TRPC3 mRNA.
   Oncogene. 2022 Jul 22. pii: 10.1038/s41388-022-02411.
   PubMed     Abstract available
   
   
   June 2022
10. HUANG C, Lv X, Chen P, Liu J, et al
    Human papillomavirus targets the YAP1-LATS2 feedback loop to drive cervical cancer development.
    Oncogene. 2022 Jun 27. pii: 10.1038/s41388-022-02390.
    PubMed     Abstract available
    
    
    
11. MOTOHARA T, Masuda K, Morotti M, Zheng Y, et al
    Correction to: An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.
    Oncogene. 2022 Jun 6. pii: 10.1038/s41388-022-02356.
    PubMed    
    
    
    May 2022
12. GEORGIOU M, Ntavelou P, Stokes W, Roy R, et al
    Correction: ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.
    Oncogene. 2022 May 30. pii: 10.1038/s41388-022-02354.
    PubMed    
    
    
    April 2022
13. ZHU S, Zhang C, Cao D, Bai J, et al
    Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.
    Oncogene. 2022 Apr 25. pii: 10.1038/s41388-022-02277.
    PubMed     Abstract available
    
    
    
14. KOMATSU M, Nakamura K, Takeda T, Chiwaki F, et al
    Aurora kinase blockade drives de novo addiction of cervical squamous cell carcinoma to druggable EGFR signalling.
    Oncogene. 2022;41:2326-2339.
    PubMed     Abstract available
    
    
    March 2022
15. GEORGIOU M, Ntavelou P, Stokes W, Roy R, et al
    ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.
    Oncogene. 2022 Mar 18. pii: 10.1038/s41388-022-02251.
    PubMed     Abstract available
    
    
    February 2022
16. YOSHIDA A, Phillips-Mason P, Tarallo V, Avril S, et al
    Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss.
    Oncogene. 2022 Feb 24. pii: 10.1038/s41388-022-02243.
    PubMed     Abstract available
    
    
    
17. KWON J, Choi H, Ware AD, Morillo BC, et al
    USP13 promotes development and metastasis of high-grade serous ovarian carcinoma in a novel mouse model.
    Oncogene. 2022 Feb 16. pii: 10.1038/s41388-022-02224.
    PubMed     Abstract available
    
    
    
18. LIAO Y, Huang J, Liu P, Zhang C, et al
    Downregulation of LNMAS orchestrates partial EMT and immune escape from macrophage phagocytosis to promote lymph node metastasis of cervical cancer.
    Oncogene. 2022 Feb 12. pii: 10.1038/s41388-022-02202.
    PubMed     Abstract available
    
    
    
19. MOTA A, Oltra SS, Selenica P, Moiola CP, et al
    Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression.
    Oncogene. 2022 Feb 10. pii: 10.1038/s41388-022-02221.
    PubMed     Abstract available
    
    
    
20. LIN L, Shi K, Zhou S, Cai MC, et al
    SOX17 and PAX8 constitute an actionable lineage-survival transcriptional complex in ovarian cancer.
    Oncogene. 2022 Feb 5. pii: 10.1038/s41388-022-02210.
    PubMed     Abstract available
    
    
    January 2022
21. LI J, Zheng C, Wang M, Umano AD, et al
    ROS-regulated phosphorylation of ITPKB by CAMK2G drives cisplatin resistance in ovarian cancer.
    Oncogene. 2022 Jan 18. pii: 10.1038/s41388-021-02149.
    PubMed     Abstract available
    
    
    
22. JAMES NE, Woodman M, Ribeiro JR
    Prognostic immunologic signatures in epithelial ovarian cancer.
    Oncogene. 2022 Jan 14. pii: 10.1038/s41388-022-02181.
    PubMed     Abstract available
    
    
    
23. KAN T, Zhang S, Zhou S, Zhang Y, et al
    Single-cell RNA-seq recognized the initiator of epithelial ovarian cancer recurrence.
    Oncogene. 2022 Jan 7. pii: 10.1038/s41388-021-02139.
    PubMed     Abstract available
    
    
    November 2021
24. YIN L, Zeng Y, Zeng R, Chen Y, et al
    Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer.
    Oncogene. 2021 Nov 19. pii: 10.1038/s41388-021-02117.
    PubMed     Abstract available
    
    
    
25. BOUDHRAA Z, Zaoui K, Fleury H, Cahuzac M, et al
    NR1D1 regulation by Ran GTPase via miR4472 identifies an essential vulnerability linked to aneuploidy in ovarian cancer.
    Oncogene. 2021 Nov 6. pii: 10.1038/s41388-021-02082.
    PubMed     Abstract available
    
    
    May 2021
26. KUMAGAI K, Takanashi M, Ohno SI, Harada Y, et al
    WAPL induces cervical intraepithelial neoplasia modulated with estrogen signaling without HPV E6/E7.
    Oncogene. 2021;40:3695-3706.
    PubMed     Abstract available
    
    
    April 2021
27. ALI R, Alblihy A, Miligy IM, Alabdullah ML, et al
    Molecular disruption of DNA polymerase beta for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.
    Oncogene. 2021;40:2496-2508.
    PubMed     Abstract available
    
    
    March 2021
28. NI M, Li J, Zhao H, Xu F, et al
    BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.
    Oncogene. 2021 Mar 12. pii: 10.1038/s41388-021-01735.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: